参考文献
1: Wu DC, Kuo CH, Tsay FW, Hsu WH, Chen A, Hsu PI. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. Medicine (Baltimore). 2016 Mar;95(11):e2698. doi: 10.1097/MD.0000000000002698. PubMed PMID: 26986096; PubMed Central PMCID: PMC4839877.
2: Prapitpaiboon H, Mahachai V, Vilaichone RK. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. Asian Pac J Cancer Prev. 2015;16(10):4353-6. PubMed PMID: 26028098.
3: Parekh PJ, Oldfield EC 4th, Johnson DA. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium). Expert Opin Pharmacother. 2014 Jun;15(9):1215-22. doi: 10.1517/14656566.2014.911841. Epub 2014 Apr 21. Review. PubMed PMID: 24749891.
4: Attumi TA, Graham DY. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter. 2014 Aug;19(4):319-22. doi: 10.1111/hel.12126. Epub 2014 Apr 3. PubMed PMID: 24698653; PubMed Central PMCID: PMC4111781.
5: Oldfield Iv EC, Parekh PJ, Johnson DA. Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis. Expert Rev Gastroenterol Hepatol. 2016 Aug 31. [Epub ahead of print] PubMed PMID: 27580358.
6: Peura DA, Pilmer B, Hunt B, Mody R, Perez MC. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013 Nov;38(10):1303-11. doi: 10.1111/apt.12504. Epub 2013 Sep 30. PubMed PMID: 24118079.
7: Wu MS, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013 Jul;38(2):190-201. doi: 10.1111/apt.12349. Epub 2013 May 29. PubMed PMID: 23718547.
8: Goh KL, Choi MG, Hsu PI, Chun HJ, Mahachai V, Kachintorn U, Leelakusolvong S, Kim N, Rani AA, Wong BC, Wu J, Chiu CT, Shetty V, Bocobo JC, Chan MM, Lin JT. Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66. doi: 10.5056/jnm15150. Review. PubMed PMID: 26932927; PubMed Central PMCID: PMC4930293.
9: Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clin Exp Gastroenterol. 2016 Jul 13;9:163-72. doi: 10.2147/CEG.S91602. eCollection 2016. Review. PubMed PMID: 27471402; PubMed Central PMCID: PMC4948703.
10: Peura DA, Pilmer B, Hunt B, Mody R, Perez MC. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Aliment Pharmacol Ther. 2013 Apr;37(8):810-8. doi: 10.1111/apt.12270. Epub 2013 Mar 4. PubMed PMID: 23451835; PubMed Central PMCID: PMC3613742.
11: Grabowski B, Lee RD. Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32. doi: 10.2165/11630930-000000000-00000. PubMed PMID: 22455762.
12: Frye JW, Peura DA. Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag. 2015 Oct 30;11:1649-56. doi: 10.2147/TCRM.S66680. eCollection 2015. Review. PubMed PMID: 26586949; PubMed Central PMCID: PMC4634831.
13: Li J, Wang L, Ye YQ, Fu X, Ren Q, Zhang H, Deng Z. Improving the solubility of dexlansoprazole by cocrystallization with isonicotinamide. Eur J Pharm Sci. 2016 Mar 31;85:47-52. doi: 10.1016/j.ejps.2016.01.029. Epub 2016 Feb 1. PubMed PMID: 26836368.
14: Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3;59(14):1304-11. doi: 10.1016/j.jacc.2011.12.024. Erratum in: J Am Coll Cardiol. 2012 Aug 7;60(6):566-7. PubMed PMID: 22464259.
15: Kukulka M, Nudurupati S, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease. Clin Exp Gastroenterol. 2014 Dec 8;7:461-71. doi: 10.2147/CEG.S67672. eCollection 2014. PubMed PMID: 25525378; PubMed Central PMCID: PMC4266249.
